Cargando…

Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study

BACKGROUND: Several countries have authorised or begun using a booster vaccine dose against COVID-19. Policy makers urgently need evidence of the effectiveness of additional vaccine doses and its clinical spectrum for individuals with complete primary immunisation schedules, particularly in countrie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jara, Alejandro, Undurraga, Eduardo A, Zubizarreta, José R, González, Cecilia, Pizarro, Alejandra, Acevedo, Johanna, Leo, Katherinne, Paredes, Fabio, Bralic, Tomás, Vergara, Verónica, Mosso, Marcelo, Leon, Francisco, Parot, Ignacio, Leighton, Paulina, Suárez, Pamela, Rios, Juan Carlos, García-Escorza, Heriberto, Araos, Rafael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034854/ https://www.ncbi.nlm.nih.gov/pubmed/35472300 http://dx.doi.org/10.1016/S2214-109X(22)00112-7

Ejemplares similares

Effectiveness of an inactivated SARS-CoV-2 vaccine in children and adolescents: a large-scale observational study
por: Jara, Alejandro, et al.
Publicado: (2023)

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
por: Jara, Alejandro, et al.
Publicado: (2021)

Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile
por: Acevedo, Johanna, et al.
Publicado: (2023)

Effectiveness of CoronaVac in children 3–5 years of age during the SARS-CoV-2 Omicron outbreak in Chile
por: Jara, Alejandro, et al.
Publicado: (2022)

Effectiveness of the second COVID-19 booster against Omicron: a large-scale cohort study in Chile
por: Jara, Alejandro, et al.
Publicado: (2023)

Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
por: Ranzani, Otavio T., et al.
Publicado: (2022)

Homologous and Heterologous Covid-19 Booster Vaccinations
por: Atmar, Robert L., et al.
Publicado: (2022)

Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans
por: Mayr, Florian B., et al.
Publicado: (2022)

Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron
por: Accorsi, Emma K., et al.
Publicado: (2022)

AEs after homologous versus heterologous COVID-19 booster
Publicado: (2022)

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
por: Wang, Xun, et al.
Publicado: (2022)

Tool for Estimating the Probability of Having COVID-19 With 1 or More Negative RT-PCR Results
por: Jara, Alejandro, et al.
Publicado: (2021)

Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people
por: Rouco, Santiago Oviedo, et al.
Publicado: (2022)

Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipients
por: Gaete-Argel, Aracelly, et al.
Publicado: (2023)

Frequency and Nuisance Level of Adverse Events in Individuals Receiving Homologous and Heterologous COVID-19 Booster Vaccine
por: Rzymski, Piotr, et al.
Publicado: (2022)

Comparison of Homologous and Heterologous Booster SARS-CoV-2 Vaccination in Autoimmune Rheumatic and Musculoskeletal Patients
por: Honfi, Dániel, et al.
Publicado: (2022)

Overstated conclusions of a non-inferiority trial testing immunogenicity and safety of homologous and heterologous booster vaccination
por: Vadrevu, Krishna Mohan
Publicado: (2023)

Safety and Immunogenicity of Inactivated Bacillus subtilis Spores as a Heterologous Antibody Booster for COVID-19 Vaccines
por: Sung, Johnny Chun-Chau, et al.
Publicado: (2022)

Investigation of Adverse Events Experienced by Healthcare Workers following Immunization with Homologous or Heterologous COVID-19 Booster Vaccinations
por: Wei, Yunhua, et al.
Publicado: (2022)

Overstated conclusions of a non-inferiority trial testing immunogenicity and safety of homologous and heterologous booster – authors' reply
por: Rose, Winsley, et al.
Publicado: (2023)

Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis
por: Deng, Jie, et al.
Publicado: (2022)

EFFECTS OF HOMOLOGOUS AND HETEROLOGOUS BOOSTER VACCINATIONS OF THE INACTIVATED DUAL-ADJUVANTED VACCINE VLA2001 AGAINST COVID-19 INCLUDING VARIANTS OF CONCERN: A PHASE 3 RANDOMIZED CLINICAL TRIAL
por: Wressnigg, N., et al.
Publicado: (2023)

Comparing the SARS-CoV-2-specific antibody response in human milk after homologous and heterologous booster vaccinations
por: Mulleners, Sien J., et al.
Publicado: (2023)

Safety Profile of Homologous and Heterologous Booster COVID-19 Vaccines in Physicians in Quito-Ecuador: A Cross-Sectional Study
por: Flores-Lastra, Nancy, et al.
Publicado: (2023)

Effect of challenge of pigs previously immunised with inactivated vaccines containing homologous and heterologous Mycoplasma hyopneumoniae strains
por: Villarreal, Iris, et al.
Publicado: (2012)

Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel
por: Park, Sungsoo, et al.
Publicado: (2022)

Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection
por: Hyun, Hakjun, et al.
Publicado: (2023)

Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients
por: Zhang, Lei, et al.
Publicado: (2023)

Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months
por: Low, Ee Vien, et al.
Publicado: (2022)

Homologous or Heterologous COVID-19 Booster Regimens Significantly Impact Sero-Neutralization of SARS-CoV-2 Virus and Its Variants
por: Buathong, Rome, et al.
Publicado: (2022)

Homologous booster immunization with an inactivated vaccine induced robust antibody response in healthcare workers: A retrospective study
por: Wen, Gui-Ping, et al.
Publicado: (2023)

ACTION ON FIBROBLASTS OF EXTRACTS OF HOMOLOGOUS AND HETEROLOGOUS TISSUES
por: Carrel, Alexis, et al.
Publicado: (1923)

μ-Opioid receptor desensitization: homologous or heterologous?
por: Llorente, Javier, et al.
Publicado: (2012)

A Cross-Sectional Study of Untoward Reactions Following Homologous and Heterologous COVID-19 Booster Immunizations in Recipients Seventeen Years of Age and Older
por: Tamburro, Manuela, et al.
Publicado: (2022)

Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial
por: Mrak, Daniel, et al.
Publicado: (2022)

Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose
por: Gareayaghi, Nesrin, et al.
Publicado: (2022)

Protective efficacy and immune responses by homologous prime-booster immunizations of a novel inactivated Salmonella Gallinarum vaccine candidate
por: Won, Gayeon, et al.
Publicado: (2016)

Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant
por: Zuo, Fanglei, et al.
Publicado: (2022)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

Heterologous Prime-Boost Vaccination with Inactivated Influenza Viruses Induces More Effective Cross-Protection than Homologous Repeat Vaccination
por: Bhatnagar, Noopur, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_idutsj1c6i34v507078a6s082a